AstraZeneca: Lung Neoplasms trials

The registry lists 63 Lung Neoplasms studies with AstraZeneca as lead sponsor. 12 are open to participants now and 14 have results posted.

Phase 1 8Phase 2 16Phase 3 9Phase 4 1No phase 30(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Screen for Lung Cancer in High-risk Individuals Who Have Never Smoked Using Low-dose Computed Tomography (LDCT).Not yet recruitingNCT07914881
• TROP2 NMR Concordance StudyRecruitingNCT07624318
• Observational Study That Will Analyse the Spread and Stratification of Lung Cancer Risk Using Artificial IntelligenceNot yet recruitingNCT07617636
• Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in ChinaRecruitingNCT07593248
• Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm StudyRecruitingNCT07295821Phase 2
• Lung Cancer Screening Implementation Project in the Brazilian Public Health Care System (LUSIP)Not yet recruitingNCT07279948
• Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.RecruitingNCT07279935Phase 4
• LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in CanadaRecruitingNCT07143110
• DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment PatternsRecruitingNCT07109154
• Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical RecordsNot yet recruitingNCT06842056
• Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.RecruitingNCT06376097
• Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingNCT05061550Phase 2
• Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLCTerminatedNCT05215951Phase 2Results posted
• Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.CompletedNCT04642469Phase 3Results posted
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyActive, not recruitingNCT03703297Phase 3Results posted
• A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With OsimertinibCompletedNCT03239340Phase 2Results posted
• T790M Plasma Testing Methodology Comparison and Clinical ValidationCompletedNCT02997501Phase 3Results posted
• Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLCCompletedNCT02474355Phase 3Results posted
• Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung CancerCompletedNCT02179671Phase 2Results posted
• Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung CancerTerminatedNCT02087241Phase 2Results posted
• Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung CancerCompletedNCT01605916Phase 1Results posted
• Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous TreatmentCompletedNCT01530334Phase 2Results posted
• ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer StudyCompletedNCT00745875Phase 2Results posted
• Iressa Follow-up TrialCompletedNCT00357734Phase 3Results posted
• First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) MutationCompletedNCT00344773Phase 2Results posted
• Phase II Iressa & Carbo/Gem in NSCLCCompletedNCT00264498Phase 2Results posted
• ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsCompletedNCT06973161
• Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast CancerCompletedNCT06827132
• A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Active, not recruitingNCT06606847Phase 2
• Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) StudyActive, not recruitingNCT06494241
• Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLCActive, not recruitingNCT06376084
• To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR MutationsActive, not recruitingNCT06194448Phase 2
• A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingNCT05941897Phase 2
• Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.Active, not recruitingNCT05817110
• A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyActive, not recruitingNCT05450692Phase 3
• Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCActive, not recruitingNCT05374603Phase 2
• A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid TumoursTerminatedNCT05363605Phase 1/2
• Reveal the Patterns of Presentation, Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia:CompletedNCT04836975
• Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)CompletedNCT04068168
• Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)CompletedNCT04031898
• Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR MutationActive, not recruitingNCT03833154Phase 3
• Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in BelgiumCompletedNCT03761901
• A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer PatientsCompletedNCT03725475
• Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive PatientsCompletedNCT03137264
• Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)TerminatedNCT03053297
• Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLCCompletedNCT02908750Phase 1
• National Lung Cancer Registry in Men and Women Based on Diagnosis in AlgeriaCompletedNCT02725892
• A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursCompletedNCT02586987Phase 1
• LUMINIST: LUng Cancer Molecular Insights Non Interventional StudyCompletedNCT02300831
• A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung CancerCompletedNCT02000947Phase 1
• Gefitinib Usage and Outcomes in Routine TreatmentCompletedNCT01818947
• Retrospective Study in a NSCLC M+ pCompletedNCT01795352
• Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.CompletedNCT01525199
• Descriptive Pharmacoepidemiological Study of Patients Treated With IressaCompletedNCT01448187
• Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in ThailandCompletedNCT01130961
• Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLINCompletedNCT00831909
• An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing ChemotherapyTerminatedNCT00721981
• Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer PatientsCompletedNCT00621361Phase 1
• A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)CompletedNCT00600496Phase 1
• Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid TumoursCompletedNCT00475956Phase 1
• Phase II Iressa Versus Vinorelbine (INVITE)CompletedNCT00256711Phase 2
• ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung CancerStatus unknownNCT00006049Phase 3
• ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung CancerStatus unknownNCT00006048Phase 3